Modulation of eCB activity, using new-generation CB1R antagonists and also improvement of lifestyle factors, may serve as complex therapy for obesity-related metabolic disorders, such as IR and diabetes mellitus. Here, CNR1 is linked to obesity due to melanocortin 4 receptor deficiency.